Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00067301 · ClinicalTrials.gov registry record · Phase 3
PUFA Augmentation in Treatment of Major Depression
A Phase 3 study, sponsored by National Center for Complementary and Integrative Health (NCCIH).
- Completed
- Registry status
- Phase 3
- Development phase
- 60
- Enrollment target
NCT00067301 is a Phase 3 study that has completed, run by National Center for Complementary and Integrative Health (NCCIH). The registered enrollment target is 60 participants.
The verdict
NCT00067301, a Phase 3 study, has completed, sponsored by National Center for Complementary and Integrative Health (NCCIH).
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 60 participants
- Enrollment target
Study Summary
The purpose of this study is to determine if omega-3 fatty acid EPA will enhance and speed up response to antidepressant therapy with Celexa (Citalopram) in people suffering from Major Depressive Disorder. All patients will receive Celexa, 50% will receive EPA, 50% placebo EPA.
Interventions
- DRUG Citalopram
- DRUG Polyunsaturated Fatty Acids (PUFA)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2003-09 |
| Est. Completion | 2007-04 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00067301
The ClinicalTrials.gov registry entry for NCT00067301 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Center for Complementary and Integrative Health (NCCIH), which has 203 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Citalopram is the first listed.
NCT00067301 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00067301 about?
NCT00067301 is a clinical study titled "PUFA Augmentation in Treatment of Major Depression". The purpose of this study is to determine if omega-3 fatty acid EPA will enhance and speed up response to antidepressant therapy with Celexa (Citalopram) in people suffering from Major Depressive Disorder. All patients will receive Celexa, 50% will receive EPA, 50% placebo EPA.
What is the current status of trial NCT00067301?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 60 participants. The study started on 2003-09. Estimated completion is 2007-04.
What interventions are being tested in trial NCT00067301?
The interventions under investigation include: Citalopram (DRUG), Polyunsaturated Fatty Acids (PUFA) (DRUG).
Who is sponsoring clinical trial NCT00067301?
This trial is sponsored by National Center for Complementary and Integrative Health (NCCIH), which has 203 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.